论文部分内容阅读
Since SAHA (2006),Belinostat (2014),Panobinostat (2015),Chidamide and Romidepsin (FK228,2010) were approved for the treatment of cutaneous T-cell lymphoma,inhibition of histone deacetylases (HDACs) have became a validated approach to the treatment for cancer.